Evidence map›Paper›PMID 24848109›Full record

ArticlePloS one2014

Extending the Schizosaccharomyces pombe molecular genetic toolbox.

Dorota Fennessy, Agnes Grallert, Andrea Krapp, Adisa Cokoja, Alan J Bridge, Janni Petersen, Avinash Patel, Victor A Tallada, Elvan Boke, Ben Hodgson and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Characterization of the Swi6/HP1 binding motif in its partner protein reveals the basis for the functional divergence of the HP1 family proteins in fission yeast.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Updates inJournal of fungi (Basel, Switzerland) · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Dorota FennessyCell Division Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Agnes GrallertCell Division Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Andrea KrappSwiss Institute for Experimental Cancer Research, École polytechnique fédérale de Lausanne, Lausanne, Switzerland.
Adisa CokojaSwiss Institute for Experimental Cancer Research, École polytechnique fédérale de Lausanne, Lausanne, Switzerland.
Alan J BridgeCell Division Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Janni PetersenCell Division Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Avinash PatelCell Division Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Victor A TalladaCell Division Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Elvan BokeCell Division Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Ben HodgsonCell Division Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Viesturs SimanisSwiss Institute for Experimental Cancer Research, École polytechnique fédérale de Lausanne, Lausanne, Switzerland.
Iain M HaganCell Division Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
Cancer Research UK Manchester Institute · GBUniversity of Manchester · GBÉcole Polytechnique Fédérale de Lausanne · CH

Funding

Cancer Research UK 11178Cancer Research UK 16406Cancer Research UK C147/A6058
6 · The paper itself

Abstract

Targeted alteration of the genome lies at the heart of the exploitation of S. pombe as a model system. The rate of analysis is often determined by the efficiency with which a target locus can be manipulated. For most loci this is not a problem, however for some loci, such as fin1+, rates of gene targeting below 5% can limit the scope and scale of manipulations that are feasible within a reasonable time frame. We now describe a simple modification of transformation procedure for directing integration of genomic sequences that leads to a 5-fold increase in the transformation efficiency when antibiotic based dominant selection markers are used. We also show that removal of the pku70+ and pku80+ genes, which encode DNA end binding proteins required for the non-homologous end joining DNA repair pathway, increases the efficiency of gene targeting at fin1+ to around 75-80% (a 16-fold increase). We describe how a natMX6/rpl42+ cassette can be used for positive and negative selection for integration at a targeted locus. To facilitate the evaluation of the impact of a series of mutations on the function of a gene of interest we have generated three vector series that rely upon different selectable markers to direct the expression of tagged/untagged molecules from distinct genomic integration sites. pINTL and pINTK vectors use ura4+ selection to direct disruptive integration of leu1+ and lys1+ respectively, while pINTH vectors exploit nourseothricin resistance to detect the targeted disruption of a hygromycin B resistance conferring hphMX6 cassette that has been integrated on chromosome III. Finally, we have generated a series of multi-copy expression vectors that use resistance to nourseothricin or kanamycin/G418 to select for propagation in prototrophic hosts. Collectively these protocol modifications and vectors extend the versatility of this key model system.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialGenetic EngineeringGenetic VectorsGenome, BacterialSchizosaccharomycesSequence Homology, Nucleic AcidStreptothricinsTransformation, GeneticAnti-Bacterial AgentsStreptothricins

Identifiers

PMID24848109
PMCPMC4029729
OpenAlexW2149870747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.